Kyverna Therapeutics to Participate in Upcoming September Investor Conferences

Rhea-AI Summary

Kyverna Therapeutics (KYTX), a clinical-stage biopharmaceutical company focusing on cell therapies for autoimmune diseases, has announced its participation in three major investor conferences in September 2024:

• Morgan Stanley Global Healthcare Conference in New York, NY on September 4
• Wells Fargo Healthcare Conference in Boston, MA on September 5
• Cantor Global Healthcare Conference in New York, NY on September 17

At each event, Kyverna executives will engage in fireside chats and host investor meetings. This series of appearances provides significant opportunities for the company to showcase its progress and connect with potential investors.

EMERYVILLE, Calif., Aug. 21, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today that the company's executives will participate in the following investor events:

Investor Conference Details:    

• Morgan Stanley Global Healthcare Conference in New York, NY on September 4, 2024
  Format: Fireside Chat with Mike Ulz at 11:30 am EDT and host investor meetings
• Wells Fargo Healthcare Conference in Boston, MA on September 5, 2024
  Format: Fireside Chat with Derek Archila at 2:15 pm EDT and host investor meetings
• Cantor Global Healthcare Conference in New York, NY on September 17, 2024
  Format: Fireside Chat with Eric Schmidt at 10:20 am EDT and host investor meetings

Investors interested in scheduling a meeting with management during one of the investor conferences listed above should contact their Morgan Stanley, Wells Fargo, or Cantor sales representative.

About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. 

Our lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis. 

Kyverna's pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to:  Kyverna's expected participation in upcoming investor conferences; Kyverna's ongoing clinical trials; Kyverna's pipeline and the potential for Kyverna's CAR T-cell therapies to be well suited for use in B cell-driven autoimmune diseases. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna's management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. 

For more information, please visit https://kyvernatx.com.
Investor Contact:
George Thampy
Kyverna Therapeutics
InvestorRelations@kyvernatx.com

Kyverna Media Contact:
Consort Partners for Kyverna
kyvernatx@consortpartners.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/kyverna-therapeutics-to-participate-in-upcoming-september-investor-conferences-302227873.html

SOURCE Kyverna Therapeutics

FAQ

What investor conferences will Kyverna Therapeutics (KYTX) attend in September 2024?

Kyverna Therapeutics will participate in three investor conferences in September 2024: the Morgan Stanley Global Healthcare Conference in New York on September 4, the Wells Fargo Healthcare Conference in Boston on September 5, and the Cantor Global Healthcare Conference in New York on September 17.

What type of presentations will Kyverna Therapeutics (KYTX) give at the September 2024 investor conferences?

Kyverna Therapeutics will participate in fireside chat discussions at each conference and host investor meetings. The format allows for in-depth conversations about the company's progress and strategy.

How can investors schedule meetings with Kyverna Therapeutics (KYTX) management at the September 2024 conferences?

Investors interested in scheduling meetings with Kyverna Therapeutics management should contact their Morgan Stanley, Wells Fargo, or Cantor sales representative, depending on which conference they plan to attend.

What is the focus of Kyverna Therapeutics (KYTX) as a biopharmaceutical company?

Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.